Survival analysis part I: basic concepts and first analyses.

Journal article

Survival analysis is a collection of statistical procedures for data analysis where the outcome variable of interest is time until an event occurs. Because of censoring - the nonobservation of the event of interest after a period of follow-up - a proportion of the survival times of interest will often be unknown. It is assumed that those patients who are censored have the same survival prospects as those who continue to be followed, that is, the censoring is uninformative. Survival data are generally described and modelled in terms of two related functions, the survivor function and the hazard function. The survivor function represents the probability that an individual survives from the time of origin to some time beyond time t. It directly describes the survival experience of a study cohort, and is usually estimated by the KM method. The logrank test may be used to test for differences between survival curves for groups, such as treatment arms. The hazard function gives the instantaneous potential of having an event at a time, given survival up to that time. It is used primarily as a diagnostic tool or for specifying a mathematical model for survival analysis. In comparing treatments or prognostic groups in terms of survival, it is often necessary to adjust for patient-related factors that could potentially affect the survival time of a patient. Failure to adjust for confounders may result in spurious effects. Multivariate survival analysis, a form of multiple regression, provides a way of doing this adjustment, and is the subject the next paper in this series.

Authors: Clark, T; Bradburn, M; Love, S; Altman, D

• Publication status: Published
• Journal: British journal of cancer
• Volume: 89
• Issue: 2
• Pages: 232-238
• Publication date: 2003-07-01
• DOI: 10.1038/sj.bjc.6601118
• EISSN: 1532-1827
• ISSN: 0007-0920
• Language: English
• Keywords: Ovarian Neoplasms; Survival Analysis; Research Design; Risk Assessment; Humans; Female; Lung Neoplasms; Models, Theoretical; Clinical Trials as Topic